FDA's Role in Public Health:

Drug Efficacy, Safety, Quality, and Beyond

About this site:

This activity is supported by the US Food and Drug Administration (FDA) through a contract from the Department of Health and Human Services, and FDA's privacy policies apply while you are on this site.

Continuing Education Credits (CE) Released: 2/25/2016; Valid for credit through: 2/24/2019

Credits Available:

Physicians – 1.5 AMA PRA Category 1 Credit(s)
Nurses – 1.5 ANCC Contact Hours
Pharmacists – 1.5 ACPE Contact Hours
Nurse Practitioners – 1.5 AANP Contact Hours
Physician Assistants – 1.5 hours of Category I Credit

Certificates of Completion:

For users wishing to have confirmation that they have completed this course, they may choose to receive a Certificate of Completion which comes with no CE credits.

Target Audience:

The target audience for this course is healthcare professionals, including physicians, physician assistants, nurses, nurse practitioners, and pharmacists. The course can be taken for informational purposes or for Continuing Education (CE) credit.


This activity explains how U.S. public health policy has influenced and shaped the Food and Drug Administration (FDA) protections that Americans have come to expect, provides an overview of FDA’s Center for Drug Evaluation and Research, or CDER’s, role in the regulation of new drug development, marketed drugs, quality testing, and post-market surveillance, and identifies new directions for the human drug regulatory process in the United States.

Learning Objectives:

Upon completion of this activity, participants should be able to:

  • Describe and explain the drug development and review process in the United States for new drugs, generics, over-the-counter (OTC) drugs, and biosimilars
  • Outline CDER’s role in post-marketing safety surveillance for medical products
  • Identify ways CDER disseminates safety information about medical products to both health care professionals and their
  • Describe CDER initiatives and commitments for the protection of public health
  • Describe the new drug development and review process

Acknowledgement of Commercial Support:

No commercial support was received for this activity.

Disclosure Information

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content of CE disclosed to IAHB, Amedco and FDA. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­-6.2, 6.5)

All individuals in a position to control the content of CE are listed below and had no relevant financial relationship to disclose.

Elaine FrostPlannerNA
Joseph CheekPlannerNA
Kimberly ChiuPlanner, ReviewerNA
Renu LalPlanner, ReviewerNA

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of QuroumEDU and the US Food and Drug Administration (FDA). QuroumEDU is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

QuroumEDU designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses:

QuroumEDU is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by QuroumEDU and FDA. Maximum of 1.5 contact hours.

For Pharmacists:

ACPE LogoAmedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program qualifies for up to 1.5 contact hours. Full attendance is required. No partial contact hours will be awarded for partial attendance.
UAN: 0453-9999-15-152-H01-P

For Nurse Practitioners:

This program is approved for 1.5 contact hours of continuing education by the American Association of Nurse Practitioners. Program ID 15121994. This program was planned in accordance with AANP CE Standards and Policies.

For Physician Assistants:

AAPA accepts certificates of participation for educational activities certified for Category I credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category I Credit(s)™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 1.5 hours of Category I credit from completing this program.

Method of Physician Participation:

Each physician will listen to each audio self-directed module while following along with the visual slides. Upon completion, each physician will answer evaluation questions and pass a posttest with at least a score of 80% to receive their CE certificate.

Technical Requirements and Instructions:

To access the course, users will need a computer with an Internet connection, and:

  • Internet Explorer 10 or higher,
  • Firefox 43 or higher,
  • Safari 9 or higher, or
  • Any other W3C standards compliant browser

An HTML5 capable browser is required for video playback. Occasionally, other additional software may be required such as PowerPoint or Adobe Acrobat Reader. Viewing on a desktop, laptop or tablet is recommended.

Users are required to visit all screens before getting access to the Conclusion module and the posttest. To receive your certificate for CE credit, you must complete the posttest and receive a score of 80 percent or better and complete an evaluation form.

For questions about content or about technical issues, you may contact FDA:

Toll Free
(855) 543-3784, or
(301) 796-3400